
A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy
Publication
, Journal Article
Chu, QSC; Markman, B; Leighl, N; Krug, L; Rudin, C; Lathers, D; Basciano, P; Fracasso, PM; Kollia, G; Phillips, P; Kolaitis, G; Williams, D ...
Published in: Annals of Oncology
October 1, 2016
Duke Scholars
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2016
Volume
27
Start / End Page
vi494
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Chu, Q. S. C., Markman, B., Leighl, N., Krug, L., Rudin, C., Lathers, D., … Ready, N. (2016). A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy. Annals of Oncology, 27, vi494. https://doi.org/10.1093/annonc/mdw389.05
Chu, Q. S. C., B. Markman, N. Leighl, L. Krug, C. Rudin, D. Lathers, P. Basciano, et al. “A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy.” Annals of Oncology 27 (October 1, 2016): vi494. https://doi.org/10.1093/annonc/mdw389.05.
Chu QSC, Markman B, Leighl N, Krug L, Rudin C, Lathers D, et al. A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy. Annals of Oncology. 2016 Oct 1;27:vi494.
Chu, Q. S. C., et al. “A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy.” Annals of Oncology, vol. 27, Oct. 2016, p. vi494. Scopus, doi:10.1093/annonc/mdw389.05.
Chu QSC, Markman B, Leighl N, Krug L, Rudin C, Lathers D, Basciano P, Fracasso PM, Kollia G, Phillips P, Kolaitis G, Williams D, Jackson J, Ready N. A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy. Annals of Oncology. 2016 Oct 1;27:vi494.

Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2016
Volume
27
Start / End Page
vi494
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis